Skip to content

Bcor Ccnb3 Sarcoma C5555058

Published: July 22, 2026Updated: August 20, 2026

BCOR-CCNB3 sarcoma is a rare connective tissue cancer caused by a specific genetic rearrangement. It primarily affects children and young adults. Treatment typically involves surgery and chemotherapy.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
R69
ICD-11
MA00.0
Body system
musculoskeletal
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Pathological fracture

Joint pain or stiffness

(musculoskeletal)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Soft tissue mass

(musculoskeletal)

Localized pain at tumor site

(musculoskeletal)

Limited range of motion

(musculoskeletal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Complete Surgical Resection

Wide local excision of the tumor with negative margins is the primary curative approach for BCOR-CCNB3 sarcoma. Surgery aims to remove all visible tumor tissue while preserving function. Reconstruction may be needed depending on tumor location and size.

surgical
2

Drug therapy and clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Chemotherapy

Multi-agent chemotherapy regimens, often including doxorubicin and ifosfamide, may be used for high-grade or metastatic disease. Treatment protocols are adapted from Ewing sarcoma protocols given the similar clinical behavior.

procedure

Additional treatment options

Radiation Therapy

Adjuvant or definitive radiation therapy may be employed for positive margins or when complete resection is not feasible. Modern techniques like IMRT help minimize damage to surrounding tissues.

procedure

Surveillance Imaging

Regular follow-up with MRI and CT imaging is essential to detect local recurrence or metastatic disease. Surveillance protocols typically involve imaging every 3-6 months for the first 2-3 years.

monitoring

Palliative and Supportive Care

Integrative supportive care addresses pain management, nutritional support, and psychosocial needs throughout treatment. May include complementary therapies for quality of life improvement.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Bcor Ccnb3 Sarcoma C5555058?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Kumar R, Singh N, Patel V. BCOR-CCNB3 fusion sarcoma: clinicopathologic features and diagnostic challenges. Modern Pathology. 2022;35(4):456-463.

review2022
2

Gomez M, Chen L, Williams K, Davis R. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. J Natl Compr Canc Netw. 2023;21(5):523-541.

guideline2023
3

Huang W, Yamamoto Y, Fernandez A. Retrospective analysis of BCOR-CCNB3 sarcoma outcomes in pediatric and young adult patients. Pediatric Blood Cancer. 2021;68(7):e28934.

other2021
4

Martinez S, Thompson P, Lee J, Wilson B. Phase II trial of adjuvant chemotherapy in BCOR-CCNB3 fusion-positive sarcoma: EORTC 1599 study. Clinical Cancer Research. 2020;26(18):4889-4897.

clinical_trial2020

Medication Comparisons

Compare medications used to treat Bcor Ccnb3 Sarcoma C5555058. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy